The global infectious disease diagnostics market size is calculated at USD 35.39 billion in 2025 and is forecasted to reach around USD 66.73 billion by 2034, accelerating at a CAGR of 7.3% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Infectious Disease Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Infectious Disease Diagnostics Market, by Product
8.1.1 Assays & Reagents
8.1.1.1. Market Revenue and Forecast
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast
8.1.3. Software
8.1.3.1. Market Revenue and Forecast
9.1. Infectious Disease Diagnostics Market, by Disease Type
9.1.1. Hepatitis
9.1.1.1. Market Revenue and Forecast
9.1.2. Human Immunodeficiency Virus
9.1.2.1. Market Revenue and Forecast
9.1.3. Influenza
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. Infectious Disease Diagnostics Market, by Technology
10.1.1. Immunodiagnostics
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinical Microbiology
10.1.2.1. Market Revenue and Forecast
10.1.3. Polymerase Chain Reaction
10.1.3.1. Market Revenue and Forecast
10.1.4. Next-generation Sequencing
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by Disease Type
11.1.3. Market Revenue and Forecast, by Technology
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Disease Type
11.1.4.3. Market Revenue and Forecast, by Technology
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by Disease Type
11.1.5.3. Market Revenue and Forecast, by Technology
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by Disease Type
11.2.3. Market Revenue and Forecast, by Technology
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by Disease Type
11.2.4.3. Market Revenue and Forecast, by Technology
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by Disease Type
11.2.5.3. Market Revenue and Forecast, by Technology
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by Disease Type
11.2.6.3. Market Revenue and Forecast, by Technology
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by Disease Type
11.2.7.3. Market Revenue and Forecast, by Technology
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by Disease Type
11.3.3. Market Revenue and Forecast, by Technology
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by Disease Type
11.3.4.3. Market Revenue and Forecast, by Technology
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by Disease Type
11.3.5.3. Market Revenue and Forecast, by Technology
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by Disease Type
11.3.6.3. Market Revenue and Forecast, by Technology
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by Disease Type
11.3.7.3. Market Revenue and Forecast, by Technology
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by Disease Type
11.4.3. Market Revenue and Forecast, by Technology
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by Disease Type
11.4.4.3. Market Revenue and Forecast, by Technology
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by Disease Type
11.4.5.3. Market Revenue and Forecast, by Technology
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by Disease Type
11.4.6.3. Market Revenue and Forecast, by Technology
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by Disease Type
11.4.7.3. Market Revenue and Forecast, by Technology
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by Disease Type
11.5.3. Market Revenue and Forecast, by Technology
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by Disease Type
11.5.4.3. Market Revenue and Forecast, by Technology
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by Disease Type
11.5.5.3. Market Revenue and Forecast, by Technology
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Becton Dickinson and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. bioMerieus SA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bio-Rad Laboratories
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Danaher Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F Hoffman-La Roche
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Hologic Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Luminex Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Qiagen Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Thermo Fisher Scientific Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample